$HALO

AI Analysis

Generated on May 11, 2026

AI Score
72/ 100
Hold$HALO

Halozyme Therapeutics

$HALONASDAQHealthcareMid-Cap

Halozyme develops drug-delivery technologies including ENHANZE for subcutaneous delivery of biologics.

Market Cap
$12.0B
Revenue (TTM)
$0.9B
+15.0%
Net Income (TTM)
$0.35B
+20.0%
EPS (TTM)
$2.50
P/E Ratio
28.0
Dividend Yield
0.0%
52-Week Range
$38-$62
Beta
0.72
Dimension Scores
Fundamental
70
Technical
68
Sentiment
72
Risk / Reward
70
Momentum
74
FundTechSentRiskMome
Financial Health
Profitability
75moderate
Growth
77strong
Liquidity
78strong
Solvency
72strong
Efficiency
68strong

Valuation, technical analysis, investment thesis, risk assessment and more for $HALO

Free · No credit card required

Disclaimer: AI-generated analysis for educational purposes only. Not financial advice. Always consult a qualified financial advisor.

Explore more

Analyze any stock with AI

Get a structured equity research report covering fundamentals, technicals, sentiment, risk, and investment thesis — in about 60 seconds.